Latest Industry News & Trends

Emerging Companies Pursuing Ophthalmic Indications, October 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, September 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease 

Tern Therapeutics announced its launch Aug. 27, along with closing of a $15 million financing. The company also reported that it had licensed gene therapy candidates RGX-381 and RGX-181 (now design...

Emerging Companies Pursuing Ophthalmic Indications, August 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, July 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

NexThera Files IND with US FDA for Trial of Wet AMD Eye Drop Candidate

NexThera, of Busan, South Korea, announced July 16 that it had filed an investigational new drug (IND) application with the US FDA for a Phase I/IIa trial of NT-101, an eye drop candidate for wet a...

China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME

China’s DP Technology announced July 8 that it would advance DPT0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a potential oral treatment candidate for...

Emerging Companies Pursuing Ophthalmic Indications, June 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, May 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, April 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis

Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...

Emerging Companies Pursuing Ophthalmic Indications, March 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

France’s PulseSight Therapeutics Launches to Advance Non-viral Retinal Gene Therapies

France’s PulseSight Therapeutics, developing non-viral ophthalmic gene therapies, launched Feb. 28 with an undisclosed seed financing from Pureos Bioventures and ND Capital. A spokeswoman for Pulse...

Emerging Companies Pursuing Ophthalmic Indications, February 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, January 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, December 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

India’s Enzene Biosciences Launches Ranibizumab Biosimilar for Wet AMD

Enzene Biosciences announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references Lucentis, which is sol...

Emerging Companies Pursuing Ophthalmic Indications, November 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, October 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, September 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Emerging Companies Pursuing Ophthalmic Indications, August 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Verséa Ophthalmics Signs Deal to Distribute Celularity’s Amniotic Allografts in the US

Celularity and Verséa Ophthalmics announced an exclusive US commercial agreement on July 27. Verséa will distribute Celularity’s Biovance and Biovance 3L for ocular surface disease and ocular surgi...

Emerging Companies Pursuing Ophthalmic Indications, July 2023

Eyedetec Licenses to Zhaoke its Eye Lipid Mobilizer for Dry Eye

Danville, California-based Eyedetec Medical reported June 8 that it had licensed its Eye Lipid Mobilizer (ELM) for the treatment of dry eye disease to Hong Kong’s Zhaoke Ophthalmology for Greater C...

India-Based IIT Kanpur and Laurus Labs to Partner on Affordable Gene Therapies; LCA May be Target

The Indian Institute of Technology Kanpur (IIT Kanpur) and India-based Laurus Labs will collaborate on developing affordable gene therapies for India and other emerging markets, IIT Kanpur announce...

Caeregen Therapeutics, Wacker Biotech Will Collaborate on CTR-107 (Noregen) for Retinal Diseases

Caeregen Therapeutics, of Rochester, Michigan, announced June 28 that it would work with German contract manufacturer Wacker Biotech on the development and production of CTR-107 (Noregen), a regene...

Tourmaline to Advance TED Candidate Following Reverse Merger with Talaris

Nasdaq-listed Talaris Therapeutics, of Boston, will combine with privately held Tourmaline Bio, of New York, in a reverse merger that gives Tourmaline a Nasdaq listing as it advances its lead progr...